Press Release Q1 FY 2026-27 Results.
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 05 Aug 2026, 06:03 PM IST · BSE ID: 2ce1614d-d6b7-4d90-aa22-1be76463d232
View Original BSE Filing (PDF)
💡
In Simple Terms
FDC Ltd reported higher profits and revenues in its latest quarter, driven by strong international sales but offset by domestic declines.
🤖 AI Summary
- FDC Ltd reported Q1 FY27 Consolidated Profit After Tax (PAT) of Rs. 132 crores, a 9.2% increase YoY.
- Consolidated Revenue from Operations for Q1 FY27 reached Rs. 668 crores, growing 3.0% YoY.
- International Formulations (US) revenue increased by 118.4% YoY to Rs. 34 crores in Q1 FY27.
- Domestic Formulations revenue declined by 1.9% YoY to Rs. 569 crores, impacting overall growth.
- The company received U.S. FDA approval for Cefixime for Oral Suspension USP during the quarter.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
668 Rs. in crores
3.0%
EBITDA
143 Rs. in crores
1.9%
PAT
132 Rs. in crores
9.2%
Domestic Formulations Revenue
569 Rs. in crores
-1.9%
International Formulations (US) Revenue
34 Rs. in crores
118.4%
International Formulations (Non-US) Revenue
39 Rs. in crores
47.7%
APIs Revenue
24 Rs. in crores
-2.9%
🏢 How This Affects the Company
The performance of International Formulations, specifically the US business, drove revenue growth, offsetting muted performance in Domestic Formulations and APIs. Domestic Formulations still comprise approximately 85% of consolidated sales, indicating its continued significance.
Consolidated PAT increased by 9.2% to Rs. 132 crores and EPS rose to Rs. 8.14, demonstrating improved profitability. EBITDA margin slightly contracted to 21.4% from 21.6% in the prior year.
The U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL expands the company's product offerings in the US market.
The decline in Domestic Formulations revenue by 1.9% indicates a reliance on international markets for growth, with select key brands experiencing subdued performance.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the 9.2% increase in EPS to Rs. 8.14 in Q1 FY27.
🔍
Management Signal
Management's focus on international markets, particularly the US, is evident through its significant growth and recent U.S. FDA approval for a new product.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor domestic and international sales growth trends.
Updates on US business expansion and new product launches.
Performance of key domestic brands mentioned in the press release.
MEDIUM RISK
Decline in Domestic Formulations revenue, which constitutes 85% of sales, presents a risk to overall growth.
💡 Investor Takeaway
FDC Ltd reported Q1 FY27 Consolidated PAT of Rs. 132 crores, a 9.2% YoY increase, with Revenue from Operations up 3.0% to Rs. 668 crores. Growth was driven by International Formulations (US up 118.4%), while Domestic Formulations declined 1.9% to Rs. 569 crores.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Profit After Tax (PAT) increased by 9.2% YoY to Rs. 132 crores in Q1 FY27, reflecting improved earnings.
- International Formulations (US) revenue grew by 118.4% YoY to Rs. 34 crores, indicating strong performance in key export markets.
⚠️ Concerns
- Domestic Formulations revenue declined by 1.9% YoY to Rs. 569 crores, impacted by subdued performance in select key brands.
- EBITDA margin slightly decreased to 21.4% in Q1 FY27 from 21.6% in Q1 FY26, indicating a minor dip in operational efficiency.
📅 Company Track Record
FDC Ltd previously reported a Q1 FY27 standalone net profit of Rs. 13,202 lakhs and approved a Rs. 45 Lakhs solar investment. The company has a history dating back to its incorporation in 1940, with accreditations from US-FDA, UK-MHRA, MCC-RSA, and UAE.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was FDC Ltd's consolidated net profit in Q1 FY27?
FDC Ltd's consolidated Profit After Tax (PAT) was Rs. 132 crores in Q1 FY27, representing a 9.2% increase from Rs. 121 crores in Q1 FY26.
What was FDC Ltd's total revenue from operations in Q1 FY27?
FDC Ltd's consolidated Revenue from Operations stood at Rs. 668 crores in Q1 FY27, showing a 3.0% increase compared to Rs. 648 crores in Q1 FY26.
How did FDC Ltd's International Formulations (US) business perform in Q1 FY27?
The International Formulations (US) business reported revenue of Rs. 34 crores in Q1 FY27, which is a significant 118.4% YoY growth.
What was the performance of FDC Ltd's Domestic Formulations in Q1 FY27?
Domestic Formulations revenue for FDC Ltd was Rs. 569 crores in Q1 FY27, reflecting a year-on-year decline of 1.9%.
What was FDC Ltd's EBITDA and EBITDA Margin in Q1 FY27?
FDC Ltd's EBITDA for Q1 FY27 stood at Rs. 143 crores, a 1.9% YoY growth, with an EBITDA margin of 21.4%.
Questions based on this BSE filing only. For information purposes.